Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4
Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
ENCALS Predictive Survival Model in FORTITUDE-ALS
Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial
Improvement in KCCQ Scores in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in the REDWOOD HCM OLE Study
Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results from the Randomized Evaluation of Dosing with CK-3773274 in Hypertrophic Cardiomyopathy (REDWOOD-HCM) Open-Label Extension Study